Preclinical M.D. Anderson study suggests ARID1a may be useful biomarker for immunotherapy

(University of Texas M. D. Anderson Cancer Center) Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University of Texas M.D. Anderson Cancer Center. The preclinical study suggests that mutations in ARID1a could be beneficial in predicting immunotherapy success.
Source: EurekAlert! - Biology - Category: Biology Source Type: news